JP Morgan Chase’s InMed Pharmaceuticals INM Stock Holding History

JP Morgan Chase’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3	Closed	-$36K	–	6458
2021 Q1	$36K	Hold	3	–	–	﹤0.01%	5603
2020 Q4	$21K	Buy	+3	New	+$24.4K	﹤0.01%	5289

Other funds holding INM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Penserra Capital Management Orinda, California $13B AUM 71.83% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Reilly Financial Advisors La Mesa, California $1.35B AUM 22.65% 1-Year Est. Return

JP Morgan Chase's INM Position: Q2 2021 in Review

JP Morgan Chase sold out of InMed Pharmaceuticals (INM) in Q2 2021, closing a stake of 3 shares — an estimated $36K sold.

JP Morgan Chase first reported a position in INM in Q4 2020 and held it in 2 quarters. The position peaked at $36K in Q1 2021. 6 funds tracked by Wall St. Rank hold INM as of Q2 2021.

JP Morgan Chase reported no remaining InMed Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
JP Morgan Chase sold 3 InMed Pharmaceuticals shares in Q2 2021, an estimated $36K.
JP Morgan Chase first reported a position in InMed Pharmaceuticals in Q4 2020 and held it in 2 quarters.
JP Morgan Chase's InMed Pharmaceuticals position peaked at $36K in Q1 2021.
6 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2021.

Based on JP Morgan Chase's 13F filing for Q2 2021, filed 12 Aug 2021.